NASDAQ:VIVO Meridian Bioscience - VIVO Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Meridian Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$33.93▼$34.0250-Day Range$33.00▼$33.9752-Week Range$20.35▼$34.38Volume6.42 million shsAverage Volume973,737 shsMarket Capitalization$1.50 billionP/E Ratio35.02Dividend YieldN/APrice Target$34.00 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Meridian Bioscience MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.1% Upside$34.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.21Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.36 out of 5 starsMedical Sector969th out of 1,009 stocksDiagnostic Substances Industry13th out of 14 stocks 1.0 Analyst's Opinion Consensus RatingMeridian Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.00, Meridian Bioscience has a forecasted upside of 0.1% from its current price of $33.97.Amount of Analyst CoverageMeridian Bioscience has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VIVO. Previous Next 0.0 Dividend Strength Dividend YieldMeridian Bioscience does not currently pay a dividend.Dividend GrowthMeridian Bioscience does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMeridian Bioscience has received a 69.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antibodies", "Diagnostic test kits", and "Biochemical assay kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Meridian Bioscience is -1.21. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Meridian Bioscience this week, compared to 1 article on an average week.Search Interest6 people have searched for VIVO on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Meridian Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of Meridian Bioscience is held by insiders.Percentage Held by Institutions89.72% of the stock of Meridian Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 135.92.Price to Book Value per Share RatioMeridian Bioscience has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Meridian Bioscience (NASDAQ:VIVO) StockMeridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.Read More Receive VIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIVO Stock News HeadlinesMarch 30, 2023 | thestreet.comMeridian Bioscience Stock Hits New 52-Week Low (VIVO)March 26, 2023 | thestreet.comMeridian Bioscience Stock Hits New 52-Week High (VIVO)March 30, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. March 23, 2023 | usnews.comPhoenix Union Bioscience High SchoolMarch 20, 2023 | marketwatch.comGlobal "Diagnostics PCR Market" 2023: On-going Trends and Growth Insights by 2027February 1, 2023 | finanznachrichten.deMeridian Bioscience, Inc.: SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian BioscienceFebruary 1, 2023 | finance.yahoo.comMeridian Bioscience finalizes $1.53B sale to South Korean-based firmsJanuary 31, 2023 | finance.yahoo.comSD Biosensor and SJL Partners Complete Transaction to Acquire Meridian BioscienceMarch 30, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. December 29, 2022 | benzinga.comMeridian Bioscience's Return On Capital Employed OverviewDecember 13, 2022 | seekingalpha.comMeridian Biosciences: Why I Moved On But May Go Back InDecember 12, 2022 | finance.yahoo.comMeridian Bioscience Announces Anticipated Closing Date of the Pending MergerDecember 12, 2022 | finance.yahoo.comMeridian Bioscience sets closing date for $1.53 billion dealNovember 22, 2022 | seekingalpha.comMeridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67MNovember 22, 2022 | finance.yahoo.comMeridian Bioscience (VIVO) Q4 Earnings Surpass EstimatesNovember 17, 2022 | finance.yahoo.comBellRing Brands (BRBR) Beats Q4 Earnings EstimatesOctober 15, 2022 | uk.finance.yahoo.comMeridian Bioscience, Inc. (VIVO)September 28, 2022 | msn.comVivo X Fold Plus launched: Check price, specifications and other detailsSeptember 20, 2022 | seekingalpha.comVIVO Meridian Bioscience, Inc.September 15, 2022 | apnews.comINVESTIGATION ALERT: Halper Sadeh LLC Investigates VIVO, OCSL, AVLRSeptember 14, 2022 | markets.businessinsider.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVO, SAVE, AAWW, MNRLSeptember 12, 2022 | finance.yahoo.comHere's when Meridian Bioscience investors will vote on firm's $1.53B acquisitionSeptember 3, 2022 | reuters.comMeridian Bioscience IncAugust 23, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, EGY, STCNAugust 5, 2022 | finance.yahoo.comMeridian Bioscience (VIVO) Meets Q3 Earnings EstimatesAugust 5, 2022 | finance.yahoo.comMERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTSJuly 29, 2022 | nasdaq.comMeridian Obtains Re-Authorization From FDA For Revogene SARS-CoV-2 Molecular AssaySee More Headlines Receive VIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIVO Company Calendar Last Earnings11/12/2021Today3/30/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:VIVO CUSIP58958410 CIK794172 Webwww.meridianbioscience.com Phone(513) 271-3700Fax513-271-3762Employees702Year Founded1977Price Target and Rating Average Stock Price Forecast$34.00 High Stock Price Forecast$34.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.97 Trailing P/E Ratio35.02 Forward P/E Ratio40.93 P/E GrowthN/ANet Income$42.46 million Net Margins12.70% Pretax Margin16.31% Return on Equity16.74% Return on Assets13.09% Debt Debt-to-Equity Ratio0.07 Current Ratio3.63 Quick Ratio2.46 Sales & Book Value Annual Sales$333.02 million Price / Sales4.49 Cash Flow$1.78 per share Price / Cash Flow19.13 Book Value$8.41 per share Price / Book4.04Miscellaneous Outstanding Shares44,010,000Free Float42,996,000Market Cap$1.50 billion OptionableOptionable Beta0.23 Social Links Key ExecutivesJohn Patrick KennyChief Executive Officer & Executive DirectorAndrew S. KitzmillerChief Financial Officer & Executive Vice PresidentJulie SmithChief Accounting Officer, Senior VP & ControllerEmerson C. MoserSenior Vice President & General CounselLourdes WeltzienExecutive Vice President-Life ScienceKey CompetitorsNeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELCelldex TherapeuticsNASDAQ:CLDXMyriad GeneticsNASDAQ:MYGNHeskaNASDAQ:HSKAView All CompetitorsInsiders & InstitutionsETF Managers Group LLCSold 1,983 shares on 3/23/2023Ownership: 0.025%Crystalline Management Inc.Bought 244,453 shares on 3/13/2023Ownership: 0.555%Voya Investment Management LLCSold 4,947 shares on 2/28/2023Ownership: 0.037%Alliancebernstein L.P.Bought 103,510 shares on 2/16/2023Ownership: 2.982%Vestcor IncSold 2,456 shares on 2/15/2023Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions VIVO Stock - Frequently Asked Questions Should I buy or sell Meridian Bioscience stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" VIVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIVO, but not buy additional shares or sell existing shares. View VIVO analyst ratings or view top-rated stocks. What is Meridian Bioscience's stock price forecast for 2023? 2 brokers have issued 1 year price targets for Meridian Bioscience's shares. Their VIVO share price forecasts range from $34.00 to $34.00. On average, they anticipate the company's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View analysts price targets for VIVO or view top-rated stocks among Wall Street analysts. How were Meridian Bioscience's earnings last quarter? Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its quarterly earnings data on Friday, November, 12th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.03. The firm had revenue of $76.20 million for the quarter, compared to analysts' expectations of $68.40 million. Meridian Bioscience had a net margin of 12.70% and a trailing twelve-month return on equity of 16.74%. During the same quarter in the previous year, the firm posted $0.19 earnings per share. What ETFs hold Meridian Bioscience's stock? ETFs with the largest weight of Meridian Bioscience (NASDAQ:VIVO) stock in their portfolio include AltShares Event-Driven ET (EVNT) and AltShares Merger Arbitrage ETF (ARB).WisdomTree U.S. SmallCap Fund (EES). What is Jack Kenny's approval rating as Meridian Bioscience's CEO? 7 employees have rated Meridian Bioscience Chief Executive Officer Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among the company's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Meridian Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA). What is Meridian Bioscience's stock symbol? Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO." Who are Meridian Bioscience's major shareholders? Meridian Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.77%), Dimensional Fund Advisors LP (4.07%), Alliancebernstein L.P. (2.98%), Geode Capital Management LLC (2.00%), AQR Arbitrage LLC (1.83%) and Morgan Stanley (1.47%). Insiders that own company stock include Andrew S Kitzmiller, Anthony P Bihl III, Bryan T Baldasare, John Mccune Jr Rice, John P Kenny and Lourdes Weltzien. View institutional ownership trends. What is Meridian Bioscience's stock price today? One share of VIVO stock can currently be purchased for approximately $33.97. How much money does Meridian Bioscience make? Meridian Bioscience (NASDAQ:VIVO) has a market capitalization of $1.50 billion and generates $333.02 million in revenue each year. The company earns $42.46 million in net income (profit) each year or $0.97 on an earnings per share basis. How many employees does Meridian Bioscience have? The company employs 702 workers across the globe. Does Meridian Bioscience have any subsidiaries? The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.Read More How can I contact Meridian Bioscience? Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The official website for the company is www.meridianbioscience.com. The company can be reached via phone at (513) 271-3700, via email at mbi@meridianbioscience.com, or via fax at 513-271-3762. This page (NASDAQ:VIVO) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.